Replies to post #240839 on Biotech Values

[DewDiligence]

Thanks for weighing in.

Transplanters believe in SCT not because they are afraid to lose business (they can easily switch over to doing CARTs, their institutions are equipped to handle CRS), but because the jury is still out on whether CART is curative.

Even if transplanters are equipped to do CAR-T, can they make as much money per patient from CAR-T as they currently do from SCT?